Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Subscribe To Our Newsletter & Stay Updated
